Test Methods

Disintegration & Dissolution Testing for Supplements — USP <2040>

8 min read Updated June 11, 2026

A supplement that does not break down in the digestive tract delivers zero active ingredients, regardless of what the potency test says. Disintegration and dissolution testing verify that your tablets, capsules, and softgels actually release their contents where and when they should. USP <2040> is the governing method for dietary supplements, and it costs $75-200 per test to confirm your product is not a very expensive placebo.

Quick answer

Disintegration testing (USP <2040>) measures how long it takes for a tablet or capsule to break apart into small particles in a simulated gastrointestinal fluid at 37 degrees C. Dissolution testing (USP <711> and <2040>) measures how much of the active ingredient dissolves into solution over time. Disintegration costs $75-150 per test. Dissolution costs $150-400 per test. Both are essential for solid oral dosage forms. Disintegration is a simpler pass/fail test; dissolution is a quantitative release profile.

Why disintegration matters

Disintegration is the first step in bioavailability. Before your body can absorb curcumin, vitamin D, or magnesium, the tablet or capsule must physically break apart. A tablet that passes through intact is a tablet that provided zero nutritional benefit.

Common disintegration failures:

Over-compressed tablets: Excessive compression force during tableting fuses particles together so tightly that water cannot penetrate. The tablet emerges intact after 30+ minutes in the disintegration bath.
Insufficient disintegrant: Crospovidone, croscarmellose sodium, sodium starch glycolate, and other disintegrants swell on contact with water and push the tablet apart from the inside. Skimping on these excipients saves a fraction of a cent per tablet and risks disintegration failure.
Coating problems: Enteric coatings designed to survive the stomach can fail to dissolve in the small intestine. Film coatings applied too thickly can delay disintegration.
Aging effects: Disintegrants can lose effectiveness over shelf life due to moisture absorption or interaction with other ingredients. A tablet that disintegrates in 8 minutes at time zero might take 22 minutes at 24 months.
Hard gelatin capsule cross-linking: Gelatin capsules exposed to aldehydes (from botanical extracts, flavors), high humidity, or UV light can cross-link and fail to dissolve.

USP <2040> disintegration method

USP <2040> specifies two apparatus options:

Apparatus A (Basket-Rack Assembly):

Six transparent tubes, each holding one dosage unit
Tubes are fitted with a 10-mesh screen at the bottom
The rack moves up and down at 29-32 cycles per minute through a water bath at 37 +/- 2 degrees C
The immersion fluid is water for most products. Simulated gastric fluid (pH 1.2) or simulated intestinal fluid (pH 6.8) can be used depending on the product.
Pass criterion: all six units disintegrate completely within the specified time (typically 30 minutes for uncoated tablets, 60 minutes for coated tablets)

Apparatus B (Disk Method):

Same basket-rack assembly but with the addition of a perforated plastic disk placed on top of each dosage unit
The disk prevents the dosage unit from floating and provides gentle abrasion
Used primarily for capsules and softgels that tend to float or stick to the tube walls

Acceptance criteria: Stage 1 tests six units. All six must pass. If one or two fail, Stage 2 tests twelve additional units. Of the total 18 units, 16 or more must pass. This two-stage testing is described in USP <2040> and follows the same logic as USP <701> (disintegration for drug products).

Dissolution testing: beyond pass/fail

Where disintegration tells you whether the dosage form falls apart, dissolution tells you how much of the active ingredient goes into solution and how fast. This matters for:

Bioavailability correlation: For some actives, dissolution data correlates with in vivo absorption. Faster dissolution generally means faster absorption, though this is not always clinically significant.
Formulation comparison: If you change your magnesium source (oxide to bisglycinate), the dissolution profile will shift. The dissolution data confirms that the new formulation performs at least as well as the old one.
Stability indication: A drop in dissolution rate at 12 months signals physical changes in the tablet even if potency and disintegration still pass. This is an early warning that the product is degrading.
Post-approval changes: If you change your tablet press, coating process, or excipient supplier, dissolution data demonstrates equivalence between the old and new process.

USP <2040> references USP <711> (Dissolution) for the apparatus. The standard dissolution apparatus for supplements is:

Apparatus 2 (Paddle): The dosage unit is dropped into 900 mL of dissolution medium at 37 degrees C stirred by a paddle at 50-100 rpm. Samples are withdrawn at defined time points (e.g., 15, 30, 45, 60 minutes) and analyzed by HPLC or UV for the active ingredient.
Apparatus 1 (Basket): A wire mesh basket containing the dosage unit rotates at 50-100 rpm. Used when the dosage form tends to float or for capsules.

Typical costs

Test	Method	Typical price	Turnaround
Disintegration, uncoated tablets	USP <2040> Apparatus A	$75-125	3-5 business days
Disintegration, capsules or softgels	USP <2040> Apparatus A or B	$75-150	3-5 business days
Dissolution, single time point	USP <2040> / <711> Apparatus 2 + HPLC	$150-250	5-7 business days
Dissolution, multi-point profile (4-6 time points)	USP <2040> / <711> Apparatus 2 + HPLC	$250-400	7-10 business days
Dissolution method development (new product)	Lab-developed method	$1,500-5,000	10-15 business days

💡 Note

If you are testing a new formulation, start with disintegration. If it fails, you know there is a physical problem without spending on dissolution. Once disintegration passes, move to dissolution to verify release kinetics. If you are testing for a stability study, dissolution at 3-4 time points captures the release profile trend more usefully than a single time point.

How often to test

Scenario	Disintegration	Dissolution
New formulation development	Every prototype batch	Every prototype batch after disintegration passes
First production batch	Required	Recommended
Routine production	Every batch or skip-lot	Quarterly or annually for ongoing stability
Post-change (new excipient, new equipment)	Required	Required to demonstrate equivalence
Stability study (accelerated and real-time)	At every pull point (0, 3, 6, 9, 12, 18, 24 months)	At key pull points (0, 12, 24 months)

FAQ

Q: What is the difference between USP <2040> and USP <701>?

A: USP <701> (Disintegration) is part of the drug product general chapters and applies to pharmaceuticals. USP <2040> (Disintegration and Dissolution of Dietary Supplements) is specifically for dietary supplements. The apparatus, procedures, and acceptance criteria are similar, but <2040> acknowledges supplement-specific considerations like botanical matrices, enteric coatings on enzyme products, and rapid-release vs. extended-release formulations. Always reference <2040> for supplements.

Q: Do I need to test both disintegration and dissolution?

A: Disintegration is simpler and cheaper and is typically the minimum requirement for finished product release testing. Dissolution provides more information and is recommended for product development, formulation changes, and stability studies. If your product is a generic single-active tablet (e.g., 500 mg vitamin C), disintegration alone may be sufficient. If it is a novel formulation, a botanical blend, or an extended-release product, invest in dissolution testing.

Q: Can a tablet pass disintegration but fail dissolution?

A: Yes. The tablet may break apart into small particles, but the active ingredient may not dissolve from those particles if the active has poor solubility, if the dissolution medium does not match gastrointestinal conditions, or if the active forms insoluble complexes with other ingredients. Disintegration is necessary but not sufficient for bioavailability.

Q: How does enteric coating affect disintegration testing?

A: Enteric-coated products are tested in two stages: first in simulated gastric fluid (pH 1.2, 0.1 N HCl) for 1-2 hours, where the coating should remain intact and no disintegration should occur. Then the medium is changed to simulated intestinal fluid (pH 6.8 phosphate buffer), where the coating should dissolve and disintegration should occur within the specified time. Enteric coatings that fail to survive the gastric phase or fail to dissolve in the intestinal phase are non-conforming.

Q: What sample size do I need for disintegration or dissolution testing?

A: USP <2040> Stage 1 requires 6 units. Stage 2 requires 12 additional units if Stage 1 fails. For dissolution, a single run typically uses 6 units (6 individual vessels run simultaneously in a 6- or 8-vessel dissolution apparatus). Send 20-30 dosage units to cover both tests plus the potential need for re-testing.

Quick Reference

Lab Category: Physical Testing / Disintegration and Dissolution

Methods: USP <2040> (Disintegration and Dissolution of Dietary Supplements), USP <701> (Disintegration), USP <711> (Dissolution), USP <1092> (The Dissolution Procedure: Development and Validation).

Sample requirements: 20-30 capsules, tablets, or softgels per test per time point.

Turnaround: Disintegration 3-5 business days. Dissolution 5-10 business days. Method development 10-15 business days.

Accreditation: ISO 17025 with USP <2040> and/or USP <711> on the scope. Confirm the lab has the appropriate apparatus (1, 2, or basket-rack) for your dosage form.

Pricing: